Mike Wood
Research Director
vernalis
United Kingdom
Biography
Mike Wood became Research Director in February 2004. Since then, he has overseen the continued strengthening of capabilities in structure and fragment based drug discovery. Mike's focus has been on the pragmatic adaptation of the most effective methods for rapid assessment of therapeutic targets and driving projects to deliver clinical candidates. The current therapeutic focus for Vernalis research is oncology and in particular drug targets relating to cancer metabolism. Before becoming our Research Director, Mike was the Head of Pre-clinical Development for Ribotargets and prior to that Director of Biology at British Biotech. Mike started his industrial career at Smith Kline and French in 1986.
Research Interest
Dr. Mike Wood having research interest in pharmaceutical and life science, immunotherapies for the treatment of cancer and infectious diseases, Halozyme Therapeutics, therapeutics for autoimmune and inflammatory diseases, Immuno-Oncology
